RT Journal Article
SR Electronic
T1 Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak - the CoNAN study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.15.20154112
DO 10.1101/2020.07.15.20154112
A1 Sebastian Weis
A1 André Scherag
A1 Michael Baier
A1 Michael Kiehntopf
A1 Thomas Kamradt
A1 Steffi Kolanos
A1 Juliane Ankert
A1 Stefan Glöckner
A1 Oliwia Makarewicz
A1 Stefan Hagel
A1 Christina Bahrs
A1 Aurelia Kimmig
A1 Hans Proquitté
A1 Joel Guerra
A1 Bettina Löffler
A1 Mathias W. Pletz
A1 CoNAN study group.
YR 2020
UL http://medrxiv.org/content/early/2020/07/17/2020.07.15.20154112.abstract
AB Background Due to the substantial proportion of asymptomatic and mild courses many SARS-CoV-2 infections remain unreported. Therefore, assessment of seroprevalence may detect the real burden of disease. We aimed at determining and characterizing the rate of SARS-CoV-2 infections and the resulting immunity in a defined population.Methods CoNAN is a population-based cohort study in the previously quarantined community Neustadt-am-Rennsteig, Germany six weeks after a SARS-CoV-2 outbreak with 49 cases identified by PCR screening of all 883 inhabitants. The primary objective of the study was to assess SARS-CoV-2 antibody seroconversion rate using six different IgG detecting immunoassays. Secondary objectives of the study were: i.) to determine the rate of seroconversion in children; ii.) to determine potential risk factors for symptomatic vs. asymptomatic Covid19 courses; iii.) to investigate the rate of virus persistence.Findings We enrolled 626 participants (71% of the community population). All actual SARS-CoV-2 PCR tests were negative; while a total of 8·4% (52 of 620 tested) had antibodies against SARS-CoV-2 in at least two independent tests. Twenty of the antibody positive participants had previously a positive SARS-CoV-2 PCR. On the contrary, of those 38 participants with SARS-CoV-2 infection, only 20 (52·6%) were antibody positive.Interpretation Several antibody tests conducted six weeks after an outbreak of SARS-CoV-2 did not detect all previously PCR-positive tested individuals. Cautious evaluation of antibody testing strategies to assess immunity against the infection is warranted.Funding CoNAN was funded by the Thuringian Ministry for Economic Affairs, Science and Digital Society (TMWWDG).Competing Interest StatementSW received speakers fees from MSD and Infectopharm. SH received speakers fees from Pfizer, MSD and Astra Zeneca. TK speakers fees from Roche MP has participated in international advisory boards from Pfizer, Novartis, Basilea and Cubist and received speakers fees from the same companies. CB has participated in advisory boards from GSK and received speakers fees from Pfizer. All other authors do not report any conflict of interestClinical TrialDRKS00022416 (submitted)Funding StatementCoNAN was funded by the Thuringian Ministry for Economic Affairs, Science and Digital Society (TMWWDG).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted according to the current version of the Declaration of Helsinki and has been approved by the institutional ethics committees of the Jena University Hospital and the respective data protection commissioner (approval number 2020-1776) and the ethics committee of the Thuringian chamber of physicians.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request after publication of the manuscript.CIconfidence intervalGEEgeneralized estimation equationsMERS-CoVMiddle East respiratory syndrome-related coronavirusORodds ratioSARS-CoVsevere acute respiratory syndrome-related coronavirus